3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
23
Nivolumab
10
Trastuzumab
7
Gemcitabine
6
Cisplatin
6
Cetuximab
6
Docetaxel
5
spartalizumab
4
atezolizumab
4
Ipilimumab
4
Drug Therapy
4
Cyclophosphamide
4
Carboplatin
4
Capecitabine
4
palbociclib
3
fludarabine
3
cemiplimab
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Erlotinib Hydrochloride
3
Bortezomib
3
ulixertinib
2
trametinib
2
sargramostim
2
pertuzumab
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Taxes
2
TH 302
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
tisotumab vedotin
×
Head & Neck
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled